CRC cells often inhibit ferroptosis for survival, and therapeutic strategies aim to promote it
Meanwhile, cells were harvested with trypsin, diluted in antibiotics-free DMEM and counted
The "minimal initial benefit" group (approximately 5-10% of users) reported limited improvements during treatment making discontinuation effects irrelevant, typically explained by inadequate product quality with degraded or low-concentration GHK-Cu, inappropriate application technique reducing absorption, unrealistic expectations exceeding what any topical can achieve, severe underlying pathology requiring medical intervention beyond cosmetic peptides, or individual non-responsiveness to copper peptide treatment for genetic or physiological reasons
2025;9(5):e2401171
HealingMaps may earn a commission when readers sign up through this link
GHK-Cu, discovered earlier, is a naturally occurring tripeptide in human plasma, while AHK-Cu is a synthetic analog developed more recently
